Precision Imaging in Oncology: The Pivotal Role of Radiology in Cancer Diagnosis, Staging and Clinical Decision-Making.

Cancer continues to represent a major global public health challenge and remains one of the leading causes of death worldwide. Recent GLOBOCAN estimates indicate a steady rise in both cancer incidence and mortality, largely driven by population aging, urbanization, environmental exposures, and lifestyle-related risk factors (Sung et al., 2021). The increasing complexity of cancer care has created an urgent need for accurate, rapid, and personalized diagnostic approaches that can improve patient outcomes and optimize therapeutic strategies. In this evolving landscape, radiology has emerged as a fundamental pillar of modern oncology, extending far beyond its traditional diagnostic role. Over the past decade, medical imaging has undergone remarkable technological transformation. Conventional imaging modalities such as plain radiography and ultrasonography, although still valuable in initial evaluation, are now complemented by sophisticated cross-sectional and functional imaging techniques. Advances in multidetector computed tomography (MDCT), diffusion-weighted magnetic resonance imaging (DW-MRI), positron emission tomography/computed tomography (PET/CT), hybrid PET/MRI, and molecular imaging have significantly improved the ability to detect tumors at earlier stages, characterize lesion biology, and evaluate metastatic spread with greater precision (Balestrucci et al., 2026). These innovations have enabled clinicians to move from generalized treatment approaches toward more individualized and evidence-based cancer management. Radiology now plays an indispensable role across the entire cancer continuum, including screening, diagnosis, staging, treatment planning, therapeutic monitoring, and post-treatment surveillance. For example, low-dose CT has revolutionized lung cancer screening by enabling earlier detection in high-risk populations, while multiparametric MRI has become essential for evaluating prostate, brain, liver, and gynecological malignancies. Similarly, PET/CT has transformed oncologic imaging by combining anatomical and metabolic information, thereby improving the detection of occult metastases and assessment of treatment response (Hu et al., 2023). Another major advancement in oncologic radiology is the integration of artificial intelligence (AI), machine learning, and radiomics into clinical practice. These technologies allow extraction of quantitative imaging biomarkers that can predict tumor behavior, molecular characteristics, therapeutic response, and patient prognosis. AI-assisted imaging systems are increasingly supporting radiologists in lesion detection, image segmentation, workflow optimization, and decision support, ultimately enhancing diagnostic accuracy and reducing interobserver variability (Grant et al., 2026). Furthermore, radiogenomics—the integration of imaging data with genomic and molecular profiles—is paving the way for precision oncology by enabling noninvasive tumor characterization and personalized treatment selection. The role of radiologists has also evolved substantially within multidisciplinary cancer care teams. Modern oncologic management depends heavily on multidisciplinary tumor boards, where radiologists contribute critical imaging interpretations that directly influence staging, surgical planning, radiation therapy design, systemic treatment selection, and response evaluation. Their participation has become essential for ensuring accurate clinical decision-making and improving coordination among oncologists, surgeons, pathologists, and radiation specialists (Gupta et al., 2025). Despite these advances, several challenges remain, including issues related to imaging accessibility, cost, radiation exposure, standardization of AI algorithms, and ethical concerns surrounding data governance and algorithm transparency. Addressing these limitations will be crucial to ensuring equitable implementation of advanced imaging technologies worldwide. This review aims to provide a comprehensive overview of the evolving role of radiology in cancer diagnosis, staging, and clinical decision-making from 2016 to 2026. It highlights recent technological developments, emerging imaging biomarkers, the growing influence of AI-driven diagnostics, and the expanding contribution of radiology to precision oncology and multidisciplinary cancer care.

2. METHODOLOGY

This narrative review was based on literature published between January 2016 and April 2026. Relevant studies were identified from peer-reviewed journals indexed in PubMed, Scopus, Web of Science, and Google Scholar databases using keywords including:

• “oncologic radiology”
• “cancer imaging”
• “tumor staging”
• “PET/CT oncology”
• “MRI cancer diagnosis”
• “radiomics”
• “artificial intelligence in radiology”
• “clinical decision-making in oncology”

Preference was given to systematic reviews, meta-analyses, multicenter studies, consensus guidelines, and high-impact oncology imaging research.

3. Role Of Radiology In Cancer Diagnosis

Radiology has become one of the most essential components of modern cancer diagnosis. Advances in imaging technology over the past decade have significantly improved the ability to detect malignancies at earlier stages, characterize tumor biology, evaluate disease extent, and guide personalized treatment strategies. Contemporary oncologic imaging is no longer limited to identifying anatomical abnormalities; it now provides functional, metabolic, and molecular information that directly influences patient management and prognosis. The integration of artificial intelligence (AI), radiomics, and hybrid imaging modalities has further enhanced diagnostic precision and clinical efficiency.

3.1 Early Detection and Screening

Early cancer detection remains one of the most effective strategies for reducing cancer-related mortality. Radiologic screening programs have substantially improved survival outcomes by identifying malignancies before the onset of advanced disease. Imaging-based screening is now routinely implemented for several common cancers, particularly breast and lung cancers, where early intervention significantly increases treatment success rates.

• Breast Cancer Screening

Mammography continues to serve as the primary imaging modality for breast cancer screening worldwide. Over recent years, technological advancements have enhanced its diagnostic performance, especially in women with dense breast tissue where conventional mammography may have limitations. Digital breast tomosynthesis (DBT), often referred to as three-dimensional mammography, has improved lesion visualization by reducing tissue overlap and increasing cancer detection rates while simultaneously lowering recall rates (Kubiak et al., 2026). In addition to DBT, contrast-enhanced spectral mammography and abbreviated breast MRI protocols have emerged as valuable supplementary tools for high-risk populations. Multiparametric MRI, which combines morphological and functional imaging sequences, offers superior sensitivity for detecting invasive breast lesions and evaluating tumor extent. Functional techniques such as diffusion-weighted imaging further contribute to lesion characterization and treatment monitoring. Artificial intelligence has also become increasingly integrated into breast imaging workflows. AI-assisted mammographic interpretation systems can identify suspicious lesions with high sensitivity, support radiologists in image interpretation, and reduce false-negative findings. Several recent studies have demonstrated that AI-supported screening models may improve diagnostic consistency and decrease reading time, particularly in high-volume screening settings (Sabry et al., 2026; Preetam et al., 2025).

• Lung Cancer Screening

Low-dose computed tomography (LDCT) has revolutionized lung cancer screening, particularly among high-risk individuals such as long-term smokers. Compared with conventional chest radiography, LDCT allows detection of small pulmonary nodules at earlier stages when curative treatment remains possible. Large-scale screening trials have shown a significant reduction in lung cancer mortality following the implementation of LDCT screening programs. Recent developments in AI-driven computer-aided detection (CAD) systems have further enhanced the diagnostic capability of LDCT by assisting radiologists in detecting subtle pulmonary nodules and differentiating benign from potentially malignant lesions. Machine learning algorithms can also help assess nodule growth patterns and malignancy risk, thereby improving diagnostic confidence and reducing observer variability (Yazarkan et al., 2026). Beyond breast and lung cancer screening, radiology is increasingly being explored in population-based screening strategies for colorectal, prostate, and liver cancers through advanced MRI, CT colonography, and molecular imaging approaches.

3.2 Cross-Sectional Imaging in Tumor Characterization

Cross-sectional imaging techniques are central to tumor characterization because they provide detailed anatomical and functional information regarding lesion size, morphology, vascularity, metabolic activity, and surrounding tissue involvement. Computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography/computed tomography (PET/CT) represent the cornerstone modalities in contemporary oncologic imaging.

• Computed Tomography (CT)

Computed tomography remains one of the most widely used imaging modalities in oncology because of its rapid image acquisition, excellent spatial resolution, and ability to perform whole-body assessment. CT plays a critical role in the diagnosis, staging, and follow-up of many malignancies, including lung cancer, colorectal cancer, pancreatic tumors, hepatobiliary malignancies, and metastatic disease. Modern CT technologies have significantly improved image quality and diagnostic accuracy. Dual-energy CT enables enhanced tissue characterization by differentiating materials based on their energy attenuation properties, thereby improving lesion conspicuity and vascular assessment. Spectral CT imaging further enhances contrast resolution and facilitates evaluation of tumor perfusion and heterogeneity. Perfusion CT has also gained importance in oncologic imaging by providing quantitative information regarding tumor vascularity, angiogenesis, and treatment response. These advanced techniques are particularly useful for assessing highly vascular tumors and monitoring antiangiogenic therapies (Balestrucci et al., 2026).

Another important advantage of CT is its widespread availability and rapid acquisition time, making it indispensable in emergency oncologic imaging and routine cancer staging. However, concerns regarding cumulative radiation exposure continue to encourage the development of low-dose imaging protocols and AI-based dose optimization systems.

• Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging has become increasingly valuable in oncology because of its superior soft tissue contrast and absence of ionizing radiation. MRI is particularly effective in evaluating tumors located in anatomically complex regions such as the brain, pelvis, liver, and musculoskeletal system. Functional MRI techniques have greatly expanded the role of MRI in cancer diagnosis and treatment assessment. Diffusion-weighted imaging (DWI) evaluates water molecule movement within tissues and provides indirect information about tumor cellularity. Dynamic contrast-enhanced MRI (DCE-MRI) assesses tissue perfusion and vascular permeability, while MR spectroscopy offers metabolic characterization of tumors. Multiparametric MRI combines these techniques to provide comprehensive anatomical and functional evaluation. This approach has become especially important in prostate cancer, rectal cancer, gynecological malignancies, and neuro-oncology, where accurate local staging directly influences treatment planning. Whole-body MRI has also emerged as a promising radiation-free alternative for metastatic screening and surveillance, particularly in pediatric oncology and hematological malignancies. Recent advances in MRI acquisition speed and AI-assisted reconstruction techniques have improved image quality while reducing scanning time (Iima et al., 2026).

Positron Emission Tomography/Computed Tomography (PET/CT)

PET/CT combines metabolic and anatomical imaging, making it one of the most powerful tools in oncologic radiology. By detecting increased glucose metabolism within malignant tissues, PET/CT enables identification of both primary tumors and distant metastases with high sensitivity. The most commonly used radiotracer in oncology is fluorodeoxyglucose labeled with fluorine-18 (^18F-FDG). FDG PET/CT is widely utilized in lymphoma, lung cancer, melanoma, head and neck cancers, and several gastrointestinal malignancies. It is particularly valuable for detecting occult metastatic disease, assessing treatment response, and distinguishing residual tumor from post-therapeutic fibrosis. Emerging molecular tracers have further expanded the clinical applications of PET imaging. Prostate-specific membrane antigen (PSMA) PET has dramatically improved the detection of recurrent and metastatic prostate cancer, while DOTATATE PET imaging has become highly effective for evaluating neuroendocrine tumors. Hybrid PET/MRI systems represent another important innovation by combining the superior soft tissue contrast of MRI with the metabolic information obtained from PET imaging. These systems are especially promising in neuro-oncology, pelvic malignancies, and pediatric cancers where minimizing radiation exposure is desirable (Ming et al., 2020). Artificial intelligence and radiomics are increasingly being integrated into PET/CT interpretation to improve lesion segmentation, prognostic prediction, and response assessment. AI-assisted PET imaging may play a major role in future precision oncology by enabling more individualized risk stratification and therapeutic planning.

4. Radiology In Cancer Staging

Accurate cancer staging is essential for determining prognosis, selecting the most appropriate treatment strategy, and predicting therapeutic outcomes. Modern oncologic imaging has become the foundation of staging systems because it allows comprehensive assessment of tumor extent, lymph node involvement, and distant metastasis. Over the last decade, advances in radiologic techniques have significantly improved staging precision, enabling clinicians to make more informed and individualized management decisions. Imaging is now integrated into nearly every tumor classification system, particularly the TNM (Tumor–Node–Metastasis) framework, which remains the global standard for cancer staging. Contemporary radiology not only identifies the anatomical spread of disease but also provides functional and metabolic information regarding tumor biology. The emergence of hybrid imaging modalities, radiomics, and artificial intelligence (AI) has further strengthened the role of imaging in precision oncology by improving lesion characterization and reducing diagnostic uncertainty.

4.1 Local Tumor Staging

Local staging focuses on determining the size of the primary tumor, its depth of invasion, and involvement of adjacent structures. Accurate evaluation of local disease extent is crucial because it directly influences surgical planning, radiotherapy targeting, and treatment selection. Magnetic resonance imaging (MRI) has become one of the most valuable tools for local tumor staging due to its superior soft tissue contrast and multiplanar imaging capability. In rectal cancer, high-resolution pelvic MRI is routinely used to assess mesorectal fascia involvement, extramural vascular invasion, and sphincter infiltration. These findings are critical in deciding whether patients require neoadjuvant chemoradiotherapy prior to surgery (Wei & Zhang, 2026). Similarly, multiparametric MRI has transformed prostate cancer staging by improving the detection of extracapsular extension, seminal vesicle invasion, and clinically significant lesions. The integration of diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI has increased diagnostic confidence and enhanced risk stratification (Pugliesi et al., 2026). In neuro-oncology, MRI remains indispensable for evaluating brain tumors because it provides excellent visualization of tumor infiltration, edema, necrosis, and involvement of eloquent brain regions. Functional MRI and perfusion imaging further contribute to preoperative planning and treatment monitoring. Computed tomography (CT), although less sensitive than MRI for soft tissue characterization, continues to play a major role in staging thoracic and abdominal malignancies. CT is especially useful for evaluating lung tumors, pancreatic cancer, hepatobiliary malignancies, and gastrointestinal cancers because of its rapid image acquisition and whole-body imaging capability. Recent developments in radiomics have also improved local staging accuracy. Quantitative imaging features extracted from CT and MRI scans can help identify tumor heterogeneity, predict aggressive behavior, and estimate the likelihood of local invasion. These approaches are increasingly being explored as noninvasive biomarkers for personalized oncology (Zafar et al., 2026).

4.2 Nodal Staging

Assessment of regional lymph node involvement is a critical component of cancer staging because nodal metastasis is strongly associated with prognosis and treatment outcomes. Traditionally, nodal staging relied mainly on size-based imaging criteria; however, this approach has limitations because small lymph nodes may harbor metastases while enlarged nodes may simply reflect inflammatory changes. Positron emission tomography/computed tomography (PET/CT) has significantly improved nodal staging by combining anatomical and metabolic information. FDG PET/CT can identify metabolically active lymph nodes that appear normal on conventional imaging, thereby increasing staging sensitivity in several malignancies including lung cancer, lymphoma, head and neck cancers, and esophageal carcinoma (Zar et al., 2026). MRI techniques such as diffusion-weighted imaging have also shown promising results in detecting nodal metastasis, particularly in pelvic and abdominal malignancies. Advanced MRI protocols can improve differentiation between benign and malignant lymph nodes by evaluating tissue cellularity and diffusion characteristics. Artificial intelligence and radiomics are increasingly being incorporated into nodal assessment. Machine learning models can analyze subtle imaging patterns beyond human visual perception, improving prediction of nodal metastasis and reducing interobserver variability. Recent radiomics-based studies in colorectal, breast, and head and neck cancers have demonstrated encouraging accuracy in identifying metastatic lymph nodes and predicting disease progression (Wei & Zhang, 2026). The integration of imaging findings into multidisciplinary tumor board discussions has become especially important for nodal staging because treatment decisions often depend on precise evaluation of nodal disease burden.

4.3 Detection of Distant Metastases

The identification of distant metastatic disease is one of the most important objectives of cancer staging because it dramatically influences prognosis and therapeutic planning. Modern imaging modalities have substantially improved the ability to detect metastatic lesions at earlier stages, even when disease burden is minimal. Whole-body CT remains widely used for metastatic assessment because it allows rapid evaluation of the chest, abdomen, pelvis, and skeletal system. However, PET/CT has emerged as one of the most effective modalities for detecting occult metastatic disease due to its ability to identify areas of increased metabolic activity. PET/CT is particularly valuable in lung cancer, lymphoma, melanoma, and head and neck malignancies where early metastatic detection can significantly alter treatment strategies. Whole-body MRI is increasingly recognized as a highly sensitive radiation-free alternative for metastatic screening, especially in pediatric patients and hematological malignancies. Diffusion-weighted whole-body MRI has shown excellent performance in detecting bone marrow metastases, liver lesions, and peritoneal disease. Hybrid PET/MRI systems represent another important advancement in metastatic imaging. By combining the superior soft tissue contrast of MRI with the metabolic information provided by PET, these systems offer comprehensive disease assessment while reducing radiation exposure. PET/MRI has shown promising applications in prostate cancer, gynecological malignancies, and neuro-oncology (Gan et al., 2026). Novel molecular tracers have further expanded the role of PET imaging in metastatic staging. Prostate-specific membrane antigen (PSMA) PET has dramatically improved detection of recurrent and metastatic prostate cancer, while DOTATATE PET imaging has become highly sensitive for neuroendocrine tumors. Artificial intelligence is also beginning to influence metastatic staging by assisting in lesion detection, automated segmentation, and prognostic modeling. AI-supported imaging systems may improve workflow efficiency and enhance the reproducibility of metastatic assessments in the future.

Overall, radiology has evolved into a central component of modern cancer staging by providing detailed anatomical, functional, and molecular information that directly guides clinical decision-making. Continued integration of advanced imaging technologies with AI and precision medicine approaches is expected to further improve staging accuracy and individualized cancer care.

5. Radiology And Clinical Decision-Making

Radiology has evolved far beyond its traditional diagnostic role and is now deeply integrated into clinical decision-making across the entire spectrum of cancer care. Modern oncologic imaging not only identifies the presence and extent of disease but also provides critical information that guides therapeutic planning, predicts treatment response, evaluates prognosis, and supports personalized medicine. Over the last decade, advances in imaging technology, radiomics, and artificial intelligence (AI) have transformed radiology into a central decision-support tool within multidisciplinary oncology practice. In contemporary cancer management, treatment decisions are increasingly individualized based on tumor biology, molecular characteristics, and imaging findings. As a result, radiologists have become key contributors to multidisciplinary tumor boards, where imaging interpretation directly influences decisions regarding surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy. Accurate radiologic assessment helps clinicians determine whether tumors are operable, identify candidates for neoadjuvant therapy, evaluate metastatic burden, and monitor treatment effectiveness.

5.1 Imaging-Guided Treatment Planning

One of the most important contributions of radiology in oncology is its role in treatment planning. Imaging findings are essential for selecting the most appropriate therapeutic strategy and minimizing unnecessary interventions. In surgical oncology, high-resolution CT and MRI help define tumor margins, evaluate invasion into surrounding structures, and identify vascular or organ involvement. This information is critical for determining surgical feasibility and planning organ-preserving procedures. For example, pelvic MRI in rectal cancer guides surgeons by accurately assessing mesorectal fascia involvement and predicting circumferential resection margins. Radiology is equally indispensable in radiation oncology. Advanced imaging techniques enable precise tumor localization and target delineation for radiotherapy planning. Functional imaging modalities such as PET/CT and diffusion-weighted MRI can identify metabolically active tumor regions, allowing more accurate radiation dose delivery while reducing exposure to healthy tissues. Image-guided radiotherapy (IGRT) and adaptive radiotherapy have further improved treatment precision and reduced complications. In systemic therapy, imaging biomarkers increasingly help oncologists evaluate treatment suitability and predict therapeutic response. Molecular imaging with PET/CT can assess tumor metabolism and detect early biochemical changes before anatomical alterations become visible. This allows clinicians to modify ineffective treatments earlier and avoid unnecessary toxicity.

5.2 Imaging Biomarkers and Precision Oncology

The emergence of imaging biomarkers has significantly expanded the role of radiology in precision medicine. Imaging biomarkers are measurable radiologic features that provide information about tumor phenotype, biological behavior, and treatment response. Radiomics, one of the fastest-growing areas in oncologic imaging, involves the extraction of large amounts of quantitative data from CT, MRI, and PET images. These features can reveal subtle patterns related to tumor heterogeneity, vascularity, texture, and cellularity that are often not visible to the human eye. Radiomics-based models are increasingly being used to predict tumor aggressiveness, recurrence risk, metastatic potential, and survival outcomes (Zafar et al., 2026). Radiogenomics further combines imaging findings with genomic and molecular data to establish correlations between imaging phenotypes and genetic mutations. This approach supports noninvasive tumor characterization and may reduce the need for repeated tissue biopsies. Several studies have demonstrated the potential of radiogenomics in identifying molecular alterations such as EGFR mutations in lung cancer, IDH mutations in gliomas, and HER2 expression in breast cancer. Functional imaging has also become essential in precision oncology. Diffusion-weighted MRI, perfusion imaging, and PET tracers targeting specific molecular pathways provide valuable information regarding tumor microenvironment and therapeutic sensitivity. Novel PET tracers such as prostate-specific membrane antigen (PSMA) PET and DOTATATE PET have improved disease characterization and personalized treatment selection in prostate and neuroendocrine tumors, respectively. These advances are gradually shifting oncology toward a more patient-centered model in which treatment decisions are guided by individualized imaging and molecular profiles rather than solely by conventional staging systems.

5.3 Artificial Intelligence in Clinical Decision Support

Artificial intelligence is rapidly transforming oncologic radiology and has become one of the most promising innovations in cancer imaging. AI-based systems can analyze large imaging datasets with remarkable speed and accuracy, assisting radiologists in lesion detection, segmentation, classification, and prognostic assessment. Machine learning and deep learning algorithms are increasingly used to identify imaging patterns associated with malignancy, treatment response, and disease progression. AI-assisted imaging systems may improve diagnostic sensitivity, reduce interpretation time, and decrease interobserver variability, particularly in complex oncologic cases (Tong et al., 2026). In breast imaging, AI algorithms have shown promising performance in mammographic interpretation and early cancer detection. Similarly, AI-supported PET/CT analysis has demonstrated potential in predicting treatment outcomes and identifying occult metastatic disease in lung cancer, lymphoma, and head and neck malignancies. Another important application of AI is automated tumor segmentation, which facilitates radiation therapy planning and longitudinal disease monitoring. AI-driven workflow systems can also prioritize urgent cases, optimize image reconstruction, and improve operational efficiency in busy radiology departments. Despite these advantages, several limitations remain. Concerns regarding algorithm transparency, reproducibility, ethical considerations, and data privacy continue to challenge the widespread implementation of AI in clinical practice. Furthermore, most AI systems still require extensive external validation before routine adoption in oncology care.

5.4 Multidisciplinary Tumor Boards and Collaborative Oncology Care

The growing complexity of cancer management has led to increased reliance on multidisciplinary tumor boards, where specialists from radiology, oncology, surgery, pathology, and radiation therapy collaborate to develop individualized treatment plans. Radiologists play a particularly important role in these discussions because imaging findings often determine disease stage, treatment eligibility, and therapeutic response assessment. Accurate interpretation of imaging studies helps avoid overtreatment, identify disease recurrence, and guide minimally invasive interventions. The integration of advanced imaging technologies into multidisciplinary care has improved communication between specialties and enhanced evidence-based decision-making. AI-assisted imaging analysis and radiomics may further strengthen multidisciplinary collaboration by providing quantitative and predictive information that supports personalized treatment strategies (Li et al., 2025). As oncology continues to move toward precision medicine, radiology will remain central to clinical decision-making by providing comprehensive anatomical, functional, and molecular insights that improve patient outcomes and optimize cancer care.

6. Challenges And Limitations

Despite the remarkable progress in oncologic radiology over the last decade, several important challenges continue to limit the full integration and effectiveness of advanced imaging technologies in routine clinical practice. Although innovations such as artificial intelligence (AI), radiomics, hybrid imaging, and molecular diagnostics have improved cancer care, issues related to radiation safety, cost, accessibility, standardization, and ethical governance remain significant concerns. Addressing these limitations is essential for ensuring equitable, reliable, and clinically meaningful implementation of modern imaging strategies worldwide.

6.1 Radiation Exposure

One of the major concerns associated with oncologic imaging is cumulative radiation exposure, particularly in patients who require repeated imaging for diagnosis, staging, treatment monitoring, and long-term surveillance. Modalities such as computed tomography (CT) and positron emission tomography/computed tomography (PET/CT) involve ionizing radiation, and repeated examinations over time may increase the lifetime risk of radiation-induced complications. Cancer patients often undergo multiple imaging studies during the course of their disease, especially those with metastatic cancer or individuals receiving long-term follow-up. Although the clinical benefits of imaging generally outweigh the associated risks, minimizing unnecessary radiation exposure remains a critical priority in modern radiology practice. To address this issue, considerable efforts have been made to develop low-dose CT protocols, advanced image reconstruction techniques, and AI-assisted dose optimization systems. Additionally, radiation-free modalities such as magnetic resonance imaging (MRI) and ultrasound are increasingly being utilized when clinically appropriate, particularly in pediatric and young adult populations who are more sensitive to radiation effects. Hybrid imaging technologies and functional imaging methods continue to improve diagnostic performance while aiming to reduce radiation burden. Nevertheless, balancing diagnostic accuracy with patient safety remains an ongoing challenge in oncologic imaging (Mian et al., 2026).

6.2 Cost and Accessibility

Advanced imaging technologies have transformed cancer diagnosis and management; however, their high cost and limited availability continue to create disparities in healthcare access across different regions of the world. Sophisticated imaging systems such as PET/CT, PET/MRI, high-field MRI scanners, and AI-integrated platforms require substantial financial investment, specialized infrastructure, and trained personnel. In many low- and middle-income countries, access to advanced oncologic imaging remains inadequate due to economic constraints and shortages of radiologists and nuclear medicine specialists. Even in developed healthcare systems, long waiting times and resource limitations may delay diagnosis and treatment initiation. The unequal distribution of imaging resources contributes to disparities in cancer outcomes, particularly in underserved populations where early detection programs and specialized imaging services may be unavailable. Furthermore, maintenance costs, software licensing, and data storage requirements associated with AI-driven systems can impose additional financial burdens on healthcare institutions. Expanding global access to high-quality imaging services will require international collaboration, infrastructure development, workforce training, and implementation of cost-effective imaging strategies. The development of portable imaging technologies, cloud-based AI systems, and simplified imaging protocols may help improve accessibility in resource-limited settings (Zhu, 2025).

6.3 Standardization and Reproducibility Challenges

The rapid growth of radiomics and artificial intelligence in oncology has introduced new opportunities for precision medicine, but it has also highlighted important challenges related to standardization and reproducibility. Radiomics relies on extracting quantitative imaging features from CT, MRI, and PET scans; however, these features can vary significantly depending on imaging protocols, scanner types, acquisition parameters, and image reconstruction methods. Variability in image acquisition and processing can affect the reliability and generalizability of radiomics-based models. As a result, findings from one institution may not always be reproducible in other clinical settings. This lack of standardization remains one of the major barriers to the widespread clinical adoption of radiomics and AI-based imaging biomarkers.

To improve reliability, researchers emphasize the need for:

• Standardized imaging acquisition protocols
• Harmonized image processing techniques
• Large multicenter datasets
• External validation studies
• Transparent reporting guidelines

Several international initiatives have recently focused on establishing consensus recommendations for radiomics workflow standardization and AI model validation. However, further collaboration between radiologists, oncologists, data scientists, and regulatory agencies is still required to ensure reproducibility and clinical applicability (Avanzo et al., 2025). Another challenge involves data quality and annotation. AI algorithms require large, accurately labeled datasets for training, yet obtaining high-quality multicenter datasets can be difficult because of differences in institutional practices and patient privacy regulations.

6.4 Ethical and Legal Considerations

The integration of artificial intelligence into oncologic imaging has raised important ethical, legal, and regulatory concerns. While AI has the potential to improve diagnostic efficiency and clinical decision-making, questions remain regarding accountability, transparency, patient privacy, and algorithm bias. One of the primary ethical concerns involves determining responsibility when AI systems contribute to diagnostic errors or inappropriate clinical recommendations. Since many deep learning algorithms operate as “black box” systems with limited interpretability, clinicians may find it difficult to fully understand how specific decisions are generated. This lack of transparency can reduce trust in AI-assisted systems and complicate clinical accountability. Data governance is another critical issue because AI development depends heavily on large-scale patient imaging datasets. Ensuring secure data storage, patient confidentiality, and ethical data sharing remains essential. Variations in legal regulations across countries further complicate international collaboration and multicenter AI research. Algorithmic bias also represents a significant concern. AI systems trained on datasets that lack demographic diversity may perform less accurately in underrepresented populations, potentially contributing to healthcare disparities. Therefore, inclusive and representative datasets are necessary to improve fairness and reliability in AI-driven imaging applications (Abumohsen et al., 2026). Regulatory approval pathways for AI-based medical technologies are still evolving, and continuous monitoring is required to ensure patient safety and clinical effectiveness. As AI becomes more integrated into oncology practice, establishing clear ethical frameworks and regulatory standards will be crucial for responsible implementation. Overall, although modern radiology has greatly advanced cancer diagnosis and management, overcoming these technical, economic, and ethical challenges will be essential for maximizing the future impact of imaging in precision oncology.

7. Future Perspectives

The future of oncologic radiology is expected to be shaped by the continued integration of artificial intelligence (AI), radiomics, molecular imaging, and precision medicine into routine clinical practice. Emerging technologies are moving radiology beyond conventional anatomical assessment toward a more predictive and personalized approach to cancer care. AI-driven algorithms will likely enhance early cancer detection, automate image interpretation, improve workflow efficiency, and provide real-time clinical decision support with greater accuracy and consistency. At the same time, radiomics and radiogenomics are expected to play an increasingly important role in noninvasive tumor characterization by linking imaging features with molecular and genetic profiles, thereby supporting individualized treatment strategies. Hybrid imaging modalities such as PET/MRI and advanced functional imaging techniques may further improve staging accuracy, treatment monitoring, and detection of minimal residual disease while reducing radiation exposure. In the coming years, integration of imaging data with genomic, pathological, and clinical information through multidisciplinary digital platforms may enable the development of highly personalized oncology models. However, achieving these advancements will require international collaboration, standardized imaging protocols, ethical AI governance, and broader access to advanced imaging technologies to ensure equitable and effective cancer care worldwide

CONCLUSION

Radiology has become an indispensable component of modern oncology, playing a central role in cancer diagnosis, staging, treatment planning, therapeutic monitoring, and long-term surveillance. Over the past decade, substantial advancements in imaging technologies—including multidetector CT, multiparametric MRI, PET/CT, PET/MRI, radiomics, and artificial intelligence—have transformed radiology from a primarily diagnostic specialty into a comprehensive decision-support system within precision cancer care. Contemporary imaging techniques now provide not only anatomical information but also functional, metabolic, and molecular insights that enable earlier detection of malignancies, more accurate staging, and individualized treatment strategies. The integration of AI and radiomics into oncologic imaging has further improved diagnostic accuracy, workflow efficiency, and predictive modeling, supporting the growing shift toward personalized medicine. In multidisciplinary tumor boards, radiologists have become key contributors to clinical decision-making by guiding surgical planning, radiation therapy, systemic treatment selection, and response assessment. Additionally, emerging molecular imaging approaches and hybrid imaging modalities continue to enhance the evaluation of tumor biology and disease progression. Despite these remarkable developments, challenges related to radiation exposure, high costs, accessibility, standardization, and ethical governance remain important barriers to widespread implementation. Future progress in oncologic radiology will depend on collaborative research, multicenter validation studies, standardized imaging protocols, and responsible integration of AI technologies into clinical practice. Overall, radiology will continue to shape the future of cancer care by enabling more precise, patient-centered, and evidence-based oncology management. Continued innovation in imaging science and artificial intelligence is expected to further strengthen the role of radiology in improving cancer outcomes and advancing global precision medicine

REFERENCES

1. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
2. Hu, Q., Li, K., Yang, C., Wang, Y., Huang, R., & Gu, M. (2023). The role of artificial intelligence based on PET/CT radiomics in NSCLC: disease management, opportunities, and challenges. Frontiers in Oncology. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1133164/full
3. Balestrucci, G., Patanè, V., Giordano, N., Russo, A., & Urraro, F. (2026). Evolving paradigms in gastric cancer staging: From conventional imaging to advanced MRI and artificial intelligence. Diagnostics, 16(2), 284. https://www.mdpi.com/2075-4418/16/2/284
4. Grant, C. R., Patel, S. P., & Azenkot, T. (2026). Artificial intelligence tools in precision lung cancer care: From early detection to clinical decision support. Cancers, 18(9), 1455. https://www.mdpi.com/2072-6694/18/9/1455
5. Gupta, K., Butt, A. B., Farrell, A., Nanda, B., & Patlas, M. (2025). The role of radiologists in multidisciplinary tumor boards for colorectal cancer with liver metastases: A systematic review. Current Oncology Reports. https://link.springer.com/article/10.1007/s11912-025-01724-9
6. Sabry, M., Balaha, H. M., Ali, K. M., Mahmoud, A., & Gondim, D. (2026). AI-driven breast cancer diagnosis: A systematic review of imaging modalities, deep learning, and explainability. Cancers. https://www.mdpi.com/2072-6694/18/8/1305
7. Kubiak, K., Bidzi?ska, J., Bednarek, M., & Szurowska, E. (2026). Advances in breast cancer diagnostics: From screening to precision medicine. Diagnostics. https://www.mdpi.com/2075-4418/16/8/1181
8. Preetam, S., Bhattacharjee, S., & Mishra, R. (2025). Next-gen diagnostics: Artificial intelligence-powered imaging in breast cancer care. Journal of Cancer Metastasis and Treatment. https://www.oaepublish.com/articles/2394-4722.2025.74
9. Yazarkan, Y., Sonmez, G., Sahin, T. K., & Rizzo, A. (2026). Artificial intelligence in cancer screening: A narrative review of current evidence and future directions. Expert Review of Anticancer Therapy.
10. Iima, M., Saida, T., Yamada, Y., et al. (2026). Japanese Radiology 2025 updates. Canadian Association of Radiologists Journal.
11. Ming, Y., Wu, N., Qian, T., Li, X., Wan, D. Q., Li, C., & Li, Y. (2020). Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer. Frontiers in Oncology, 10, 1301. https://doi.org/10.3389/fonc.2020.01301
12. Wei, Y., & Zhang, J. (2026). Multimodal radiomics for precision management of colorectal cancer. Discover Oncology. https://link.springer.com/article/10.1007/s12672-026-04751-5
13. Pugliesi, R. A., Cannella, R., Ben Mansour, K., & Di Biagio, D. (2026). Integrating multiparametric MRI and PSMA PET imaging in prostate cancer: Toward a unified diagnostic and risk-stratification paradigm. Medicina, 62(3), 610. https://www.mdpi.com/1648-9144/62/3/610
14. Zafar, K., Jamila, M., & Rahil, M. (2026). Advances in imaging biomarkers for oncology: A comprehensive review of techniques, clinical applications and future perspectives. Journal of Cancer and Tumor International.
15. Zar, W. Y. T., Kim, M. R., Ghose, A., & Adeleke, S. (2026). The current landscape of artificial intelligence in positron emission tomography imaging across the cancer continuum. Journal of Clinical Medicine, 15(6), 2446. https://www.mdpi.com/2077-0383/15/6/2446
16. Gan, D., Ma, W., Jie, H., Huang, C., & Xu, F. (2026). Advances in functional and metabolic imaging for early tumor treatment response and resistance evaluation: A review. Cancers, 18(5), 858. https://www.mdpi.com/2072-6694/18/5/858
17. Tong, J., Chen, D., Chen, H., & Yu, T. (2026). AI-driven digital twins for bone tumors: Personalizing immunoradiotherapy and drug-based radiosensitization. Frontiers in Pharmacology. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2026.1789971/full
18. Li, D., Wang, H., Gao, F., Fu, X., & Han, J. (2025). Artificial intelligence for enhancing decision-making in multidisciplinary tumor boards for HCC in China. Hepatoma Research. https://www.oaepublish.com/articles/2394-5079.2025.67
19. Ratiu, A., & Pop, E. L. (2026). Machine learning in clinical decision making: Applications, data limitations and multidisciplinary perspectives. Applied Sciences, 16(2), 785. https://www.mdpi.com/2076-3417/16/2/785
20. Mian, T. S., Saeed, H. F., & Alatawi, E. M. (2026). Machine learning in radiation oncology. In Artificial Intelligence and Machine Learning for Cancer Care. IGI Global.
21. Zhu, H. (2025). The opportunities and challenges in deploying AI in medical imaging. Theseus Repository. https://www.theseus.fi/handle/10024/901467
22. Avanzo, M., Soda, P., Bertolini, M., Bettinelli, A., et al. (2025). Robust radiomics: A review of guidelines for radiomics in medical imaging. Frontiers in Radiology. https://www.frontiersin.org/journals/radiology/articles/10.3389/fradi.2025.1701110/full
23. Abumohsen, M., Costa-Montenegro, E., García-Méndez, S., et al. (2026). Machine learning and deep learning in lung cancer diagnostics: A systematic review of technical breakthroughs, clinical barriers, and ethical imperatives. AI Journal.
24. Mtoor, S., Rashidian, N., Messaoudi, N., Grasso, V., & Noel, F. (2026). Integrating genomics, radiomics, and pathomics in oncology: A scoping review and a framework for AI-enabled surgomics. Bioengineering, 13(1), 117. https://www.mdpi.com/2306-5354/13/1/117
25. Zhan, M., Zhou, Z., Zhang, J., Wang, X., & Li, C. (2026). Artificial intelligence in urological malignancy diagnosis and prognosis: Current status and future prospects. Canadian Journal of Urology.
26. Egbewole, B. I., Oisakede, E. O., Egbon, E., & Bello, O. J. (2026). Advancing precision oncology through hNQO1-activatable NIR-II probes: Integrating molecular imaging with artificial intelligence. Intelligent Oncology. Elsevier.
27. Li, Y. R., Li, D., Zhou, Y. W., Wang, W. E., Ma, Y. S., & Liu, X. Y. (2026). Artificial intelligence-driven early screening and diagnosis of pancreatic cancer: Technical innovations, clinical applications, and precision medicine strategies. Journal of Advanced Research. https://www.sciencedirect.com/science/article/pii/S2090123226003644
28. Fu, D., Sritharan, D. V., D'Souza, R., & Chadha, S. (2026). Artificial intelligence in lung cancer: From early detection to personalized therapy. Current Oncology Reports. https://link.springer.com/article/10.1007/s11912-026-01782-7